Description |
Imatinib mesylate is a protein¨Ctyrosine kinase inhibitor used in molecular targeted therapy to treat patients with chronic myeloid leukemia (CML). It has been approved by the FDA to treat gastrointestinal stromal tumors (GIST).
Imatinib mesylate inhibits (blocks) the Bcr¨CAbl protein tyrosine kinase to prevents the cancer cells from making more cells and causes them to die (apoptosis). It also blocks the receptor tyrosine kinase for c¨Ckit, which carries the message for the cancer cells in GIST telling them to divide, causing the cells to stop dividing and to die.
|
